RxDoctor Payments Data

Havilah Spurlock

Family · Pueblo, CONPI 1023658713

Payments from drug & device makers

$2,837in general payments, 2019–2025

Across 152 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$603
  • Scilex Pharmaceuticals Inc.$556
  • Biohaven Pharmaceutical Holding Company Ltd.$246
  • Boston Scientific$231
  • Amgen$192
  • Biohaven Pharmaceuticals, Inc.$161
  • plus $847 from 16 others

What the payments were for

  • Food & beverage$2,837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,837 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$75,632
Medicare patients
207
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl85$60,024
Buprenorphine214$45,350
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen893$29,310
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen639$24,658
Aimovig AutoinjectorErenumab-Aooe12$19,747
Nurtec OdtRimegepant Sulfate13$14,423
QuliptaAtogepant12$13,313
MovantikNaloxegol Oxalate13$11,767
ZtlidoLidocaine17$8,857
DayvigoLemborexant24$8,013
Xtampza ErOxycodone Myristate14$7,829
Nucynta ErTapentadol Hcl12$7,469
Pregabalin286$6,798
ButransBuprenorphine15$6,798
Gabapentin419$6,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er$126$75,323111 claims
PfizerNurtec Odt$145$14,42313 claims
AbbVieQulipta$603$13,31312 claims
Scilex Pharmaceuticals Inc.Ztlido$556$8,85717 claims
Eisai Inc.Dayvigo$48$8,01324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.

Other family in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →